Krystal Biotech (NASDAQ:KRYS – Get Free Report) will be announcing its earnings results before the market opens on Monday, August 5th. Analysts expect the company to announce earnings of $0.50 per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.17). The company had revenue of $45.25 million for the quarter, compared to the consensus estimate of $47.37 million. Krystal Biotech’s quarterly revenue was up 452400.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.76) EPS. On average, analysts expect Krystal Biotech to post $2 EPS for the current fiscal year and $4 EPS for the next fiscal year.
Krystal Biotech Stock Performance
KRYS opened at $191.94 on Friday. The stock has a market capitalization of $5.48 billion, a P/E ratio of 102.64 and a beta of 0.84. The company’s 50-day simple moving average is $185.14 and its two-hundred day simple moving average is $163.56. Krystal Biotech has a 52-week low of $93.95 and a 52-week high of $219.34.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Report on KRYS
Insider Transactions at Krystal Biotech
In other news, Director Julian S. Gangolli sold 20,000 shares of the stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $164.13, for a total value of $3,282,600.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Julian S. Gangolli sold 20,000 shares of the stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $164.13, for a total value of $3,282,600.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the completion of the sale, the insider now directly owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The disclosure for this sale can be found here. Company insiders own 14.10% of the company’s stock.
About Krystal Biotech
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Featured Articles
- Five stocks we like better than Krystal Biotech
- Trading Stocks: RSI and Why it’s Useful
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- What are earnings reports?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- How to Buy Cheap Stocks Step by Step
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.